Back to Results
First PageMeta Content
Endocrinology / Menopause / Menstrual cycle / Middle age / Shionogi / Estrogen / Dyspareunia / Selective estrogen receptor modulator / Vaginal lubrication / Anatomy / Human reproduction / Medicine


Company Name: Representative: Securities Code: For Inquiries, Contact: Telephone:
Add to Reading List

Document Date: 2014-11-03 11:26:19

Open Document

File Size: 66,08 KB

Share Result on Facebook

City

Ann Arbor / Turku / Osaka / Atlanta / /

Company

Hormos Medical Ltd / QuatRx Pharmaceuticals Company QuatRx Pharmaceuticals / Shionogi & Co. Ltd. / QUATRX PHARMACEUTICALS / Shionogi Pharma Inc. / Japan Shionogi & Co. / QuatRx Pharmaceuticals Company / /

Continent

Europe / /

Country

United States / Finland / /

Currency

USD / /

Event

Business Partnership / /

Facility

D pipeline / /

IndustryTerm

treatment for the symptoms / privately-held pharmaceutical / treatment of psoriasis / pharmaceutical / /

MedicalCondition

cancer / chronic symptoms / dyslipidemia / secondary hypogonadism / allergy / Metabolic Syndrome / pain / dyspareunia / Infectious Diseases / psoriasis / irritation / chronic and progressive condition / sex steroid dependent diseases / /

MedicalTreatment

estrogen therapy / /

OperatingSystem

OSE / /

Organization

FDA / /

Person

Galderma / Robert L. Zerbe / Isao Teshirogi / Noriyuki Kishida / Patrick Fourteau / /

/

Position

General Manager / Corporate Communications Dept. / CEO / President / President and CEO / CEO and Co-Founder / Representative / /

Product

Crestor / Vitamin D / /

ProvinceOrState

Georgia / /

URL

www.shionogi.co.jp / www.quatrx.com / www.shionogipharma.com / /

SocialTag